Although there is anti-tumor efficacy of dual CTLA-4/PD-1 blockade in advanced/recurrent cervical cancer, it is unclear whether combination with chemotherapy is synergistic. In COMPASSION-16, Wu et al. demonstrated improved survival outcomes of cadolinimab plus chemotherapy compared to chemotherapy alone for first-line systemic therapy for advanced/recurrent cervical cancer, suggesting a potential role of bispecific CTLA-4/PD-1 inhibitors in the frontline setting..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.11.011 | DOI Listing |
Publication Analysis
Top Keywords
cervical cancer
12
ctla-4/pd-1 blockade
8
advanced/recurrent cervical
8
integrating ctla-4/pd-1
4
blockade cervical
4
cancer management
4
management compassion-16
4
compassion-16 anti-tumor
4
anti-tumor efficacy
4
efficacy dual
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!